Open Access
Subscription or Fee Access
The Eagle Eye Approach: Comprehensive Genomics Profile[CGP]
Abstract
Ancient Medicine methods had Precision medicine concept only in traditional Ayurvedic methods. Since modern medicine adopted both genetics and genomics profiling, precision medicine is playing a major role in cancer patients' lives. This oncology Medicine has been taken to the next level while the comprehensive genomic profiling (CGP) gave hope of capturing all possible key elements through Next generation sequencing molecular approaches that contribute to the cancers. The combination of ACMG guidelines, FDA, and individual professional guidelines for therapy recommendation with all possible literature survey is making possible survival options, with less cost effective, great clinical utility options of disease management. This is attempted to discuss about how CGP has been analyzed by Clinical bioinformaticians and the impact of CGP.
References
Ménard T, Barros A, Ganter C. Clinical quality considerations when using next-generation sequenc-ing (NGS) in clinical drug development. Therapeutic Innovation & Regulatory Sci-ence. 2021 Sep;55(5):1066–74.
Metzker ML. Sequencing technologies-the next generation. Nature reviews genetics. 2010 Jan;11(1):31–46.
Genomics-driven oncology: framework for an emerging paradigm. Garraway LA., JCO. 2013;31(15):1806–14.
Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequenc-ing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. 2019:9–30.
Shylasree TS, Richa B, Lavanya G, Gulia S. Molecular Signatures of Gynecological Can-cers: Clini-cians Perspective. Indian Journal of Surgical Oncology. 2021 Apr;12(1):103–10.
Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through sec-ond-generation sequencing. Nature Reviews Genetics. 2010 Oct;11(10):685–96.
Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA oncolo-gy. 2015 Nov 1;1(8):1154–61.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine. 2013 Jun 20;368(25):2385–94.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in mel- anoma. N Engl J Med. 371:1877–1888.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001 Apr 5;344(14):1031–7.
Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a biomarker-based strategy on oncology drug devel-opment: a meta-analysis of clinical trials leading to FDA approval. Journal of the National Cancer In-stitute. 2015 Nov 1;107(11): djv253.
Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, San-ford EM, An P, Sun J. Development and validation of a clinical cancer ge-nomic profiling test based on mas-sively parallel DNA sequencing. Nature biotechnology. 2013 Nov;31(11):1023–31.
George TJ, Frampton GM, Sun J, Gowen K, Kennedy M, Greenbowe JR, Schrock AB, Ali SM, Klempner SJ, Hezel AF, Ross JS. Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: A Journal of Bioinformatics